Piribo logo
Piribo, the online destination for business intelligence for the biotech and pharmaceutical industry, has added a new report offering a guide to cardiovascular drug delivery.
“Cardiovascular Drug Delivery: Technologies, Markets and Companies”, available at http://tinyurl.com/
Drug delivery to the cardiovascular system is approached at three levels: the routes of drug delivery; the formulations;
Cell-selective targeted drug delivery has emerged as one of the most significant areas of biomedical engineering research, to optimise the therapeutic efficacy of a drug by strictly localising its pharmacological activity to a pathophysiologically relevant tissue system. These concepts have been applied to targeted drug delivery to the cardiovascular system.
According to the 262-page report, new cell-based therapeutic strategies are being developed in response to the shortcomings of available treatments for heart disease. Potential repair by cell grafting or mobilising endogenous cells holds particular attraction in heart disease, where the meager capacity for cardiomyocyte proliferation likely contributes to the irreversibility of heart failure. Cell therapy approaches include attempts to reinitiate cardiomyocyte proliferation in the adult, conversion of fibroblasts to contractile myocytes and conversion of bone marrow stem cells into cardiomyocytes.
Advances in molecular pathophysiology of cardiovascular diseases have brought gene therapy within the realm of possibility as a novel approach to treatment of these diseases. Gene therapy is likely to be less expensive due to the techniques involved; these are simpler than those involved in cardiac bypass surgery, heart transplantation and stent implantation. Gene therapy would also be a more physiologic approach to deliver vasoprotective molecules to the site of vascular lesion.
On the basis of epidemiology and total markets for cardiovascular therapeutics, the report estimates the cardiovascular drug delivery markets for the years 2008 to 2018. Markets for drug-eluting stents are calculated separately. Additionally, the role of drug delivery in developing cardiovascular markets is defined and unmet needs in cardiovascular drug delivery technologies are identified. The selected 88 companies, which either develop technologies for drug delivery to the cardiovascular system or products using these technologies, are profiled, and 68 collaborations between companies are tabulated. Supplemented with 27 tables and 6 figures, the report includes a bibliography containing 200 selected references from recent literature on the topic.
The report “Cardiovascular Drug Delivery: Technologies, Markets and Companies” is available from Piribo. For further information, please visit:
http://www.piribo.com/
Piribo product ID: JAI00004
Photo:
http://www.prlog.org/
